• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • 2.0 LPBI Brochure
  • Coronavirus, SARS-CoV-2 Portal
  • Knowledge PORTALS System (KPS)
  • Journal PharmaceuticalIntelligence.com
  • 2020-21 VISTA 1.0 LPBI
  • LPBI Group’s History
  • 2020-21 VISION – 2.0 LPBI
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • LPBI Group News
  • CALENDAR
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2020 Summer Internship Portal
  • 2021 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Vyriad – http://www.vyriad.com/

Vyriad – http://www.vyriad.com/

 

Overview

We are a privately-held clinical stage biotechnology company based in Rochester, Minnesota. We are dedicated to the development and commercialization of a new generation of targeted oncolytic virus based cancer therapies.

We have assembled and obtained exclusive rights to a portfolio of intellectual property relating to viruses that are designed to trigger oncolysis, or the destruction of cancer cells. These viruses are also designed to stimulate a patient’s own immune system to fight the cancer at the same time. Our two leading oncolytic virus product candidates, which are derived respectively from measles and vesicular stomatitis virus (commonly known as VSV) have shown promising anti-tumor activity in early stage clinical trials in an academic setting, which prompted us to license them into the company.

We were incorporated under Delaware law in May 2012 under the name Omnis International Co. In December 2015, we acquired Magnis Therapeutics, LLC, a Minnesota limited liability company, in a merger transaction pursuant to which we merged a newly-formed and wholly-owned subsidiary of our company with and into Magnis, with Magnis surviving as our wholly-owned subsidiary. In May 2016, we merged Magnis into our company and changed our name to Vyriad, Inc.

Vyriad PPM.PDF – available for review by contacting: avivalev-ari@alum.berkeley.edu

Share this:

  • Twitter
  • Facebook
  • LinkedIn
  • Print
  • Email

Like this:

Like Loading...

  • Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,064 other followers

  • Recent Posts

    • 19 of the 49 New Therapeutic Molecular Entities FDA approved in 2020 — as well as a new Cell-based therapy — are Personalized Medicines March 2, 2021
    • Happy 80th Birthday: Radioiodine (RAI) Theranostics: Collaboration between Physics and Medicine, the Utilization of Radionuclides to Diagnose and Treat: Radiation Dosimetry by Discoverer Dr. Saul Hertz, the early history of RAI in diagnosing and treating Thyroid diseases and Theranostics March 2, 2021
    • 2.0 LPBI is a Very Unique Organization  March 2, 2021
    • FDA emergency use authorization would bring the public a third vaccine for the novel coronavirus – J&J single vaccine – Authorized on 2/28/2021 March 1, 2021
    • Medical Device Representatives coach Surgeons in the Operating Rooms March 1, 2021
    • 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021 February 26, 2021
    • Inhibitory CD161 receptor recognized as a potential immunotherapy target in glioma-infiltrating T cells by single-cell analysis February 20, 2021
    • First single-course ‘curative’ CRISPR Shot by Intellia rivals Alnylam, Ionis and Pfizer February 19, 2021
    • Contribution of Nervous System Functional Deterioration to late-life Mortality: The Role Neurofilament light chain (NfL) a Blood Biomarker for the Progression of Neurological Diseases and its Correlation to Age and Life Expectancy February 19, 2021
    • COVID-19-vaccine rollout risks and challenges February 17, 2021
  • Archives

  • Categories

  • Meta

    • Register
    • Log in
    • Entries feed
    • Comments feed
    • WordPress.com
    • 2012pharmaceutical
    • Amandeep Kaur
    • Aashir Awan, Phd
    • Adina Hazan
    • Alan F. Kaul, PharmD., MS, MBA, FCCP
    • alexcrystal6
    • anamikasarkar
    • apreconasia
    • aviralvatsa
    • David Orchard-Webb, PhD
    • danutdaagmailcom
    • Demet Sag, Ph.D., CRA, GCP
    • Daniel Menzin
    • Dror Nir
    • dsmolyar
    • evelinacohn
    • Gail S Thornton
    • Irina Robu
    • jayzmit48
    • jdpmd
    • jshertok
    • kellyperlman
    • Ed Kislauskis
    • larryhbern
    • Madison Davis
    • marzankhan
    • megbaker58
    • ofermar2020
    • Dr. Pati
    • pkandala
    • Rosalind Codrington, PhD
    • ritusaxena
    • Rick Mandahl
    • sjwilliamspa
    • stuartlpbi
    • Dr. Sudipta Saha
    • tildabarliya
    • zraviv06
    • zs22

Blog at WordPress.com.

WPThemes.


loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: